This was the stock's third consecutive day of gains.
Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance. Click here to find ...
Zoetis slightly topped analyst estimates for profitability and met those for revenue in its fourth quarter. But as investors ...
Animal health company Zoetis (NYSE:ZTS) in Q4 CY2024, with sales up 4.7% year on year to $2.32 billion. On the other hand, ...
BTIG lowered the firm’s price target on Zoetis (ZTS) to $200 from $225 and keeps a Buy rating on the shares. The company delivered an in-line ...
Shares of Zoetis ( ZTS -6.17%), the leading animal pharmaceutical company, were sliding today after its 2025 guidance came up ...
Zoetis received a USDA conditional license for its H5N2 avian flu vaccine for chickens, marking a step in addressing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results